A group of 21 children with HUS underwent serial estimations of PRA and blood pressure. At time of administration PRA was 13.2 divided by 1.59 ng/ml/hr (mean + SE), in seven who were hypertensive the mean was 14.1 +/- 3.2 ng/ml/hr and despite the wide range PRA was considered to be elevated in 6 of this group. The 14 normotensive children had a mean PRA of 12.8 +/- 1.8 ng/ml/hr, only 1 patient having a value within the normal range. In 9 children PRA was normal once diuresis had been established (9 +/- 1.4 ng/ml/hr) and only two patients of this group were hypertensive at time of the study. PRA measured in 8 children 4 weeks after presentation was 7 +/- 1.6 ng/ml/hr, and 3 hypertensive children having a mean value of 7.5 ng/ml/hr and the 5 normotensive children a mean of 2.5 ng/ml/hr. The data indicate that activation of the renin-angiotensin system in HUS occurs irrespective of hypertension. Furthermore blood pressure levels were not correlated to the degree of hydration.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.
Eur J Radiol
January 2025
Department of Radiology, West China Hospital Sichuan University Chengdu Sichuan China. Electronic address:
Purpose: To develop and validate an MRI-based model for predicting postoperative early (≤2 years) recurrence-free survival (RFS) in patients receiving upfront surgical resection (SR) for beyond Milan hepatocellular carcinoma (HCC) and to assess the model's performance in separate patients receiving neoadjuvant therapy for similar-stage tumors.
Method: This single-center retrospective study included consecutive patients with resectable BCLC A/B beyond Milan HCC undergoing upfront SR or neoadjuvant therapy. All images were independently evaluated by three blinded radiologists.
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
J Gastroenterol Hepatol
January 2025
Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
Background And Aim: To assess the relationship between survival outcomes and subtypes of radiological progressive disease (PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atezo/Bev).
Methods: A total of 462 patients with Atezo/Bev-treated HCC diagnosed with radiological PD during follow-up were enrolled. PD was classified into three categories: progression or emergence of intrahepatic lesions (PD-IH), macroscopic vascular invasion (PD-MVI), and extrahepatic spread lesions (PD-EHS).
Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: a multicenter collaborative study.
Jpn J Clin Oncol
January 2025
Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461, Japan.
Background: Despite its demonstrated efficacy in prolonging overall survival (OS) and delaying skeletal-related events in the ALSYMPCA trial, the optimal timing of radium-223 initiation remains unclear. This study investigated factors influencing radium-223 treatment outcomes, including completion rates and survival.
Methods: This retrospective, multi-institutional study included 164 patients with metastatic castration-resistant prostate cancer (CRPC) who received radium-223 therapy.
Surgical margin and other prognostic factors of invasive vulvar squamous cell carcinoma: A clinicopathological mono-center study.
Heliyon
December 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
Objective: To evaluate prognostic factors in women with invasive VSCC at Sun Yat-sen University Cancer Center (SYSUCC).
Methods: 137 patients with VSCC at SYSUCC were retrospectively analyzed. The Kaplan-Meier method assessed the overall survival (OS) and progression-free survival (PFS) time.
Biochemical recurrence prediction after robot-assited radical prostatectomy (BCR-PRARP).
Heliyon
January 2025
Department of Urology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Objective: This study aimed to establish a robust predictive model for biochemical recurrence (BCR) in patients with prostate cancer who underwent robot-Assisted Radical Prostatectomy.
Material And Methods: A cohort of 1700 patients who underwent robot-assisted radical prostatectomy (RARP) for prostate cancer between August 2009 and December 2022 was included. BCR was defined as two consecutive PSA levels exceeding 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!